CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer

Poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors benefit a small percentage of ovarian cancer patients with homologous recombination (HR) deficiency (HRD), which greatly limits the applications of PARP inhibitors. Given the function of CDK9 in homologous recombination repair (HRR), h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Li, Jiajia, Zhi, Xiuling, Chen, Shuyi, Shen, Xiaoqing, Chen, Chen, Yuan, Lei, Guo, Jieyu, Meng, Dan, Chen, Mo, Yao, Liangqing
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7191097/
https://ncbi.nlm.nih.gov/pubmed/32368391
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados